← Patent-cliff monitor small molecule NUPLAZID PIMAVANSERIN TARTRATE
Loss of exclusivity February 2039 latest FDA-listed patent expiry
Drug detail Brand name NUPLAZID Active ingredient PIMAVANSERIN TARTRATE Strength EQ 34MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2018 Marketing status RX
Listed patents Patent Expires Type 10646480*PED February 2039 — 11452721*PED February 2039 — 10849891*PED February 2039 — 10449185*PED February 2039 — 10646480 August 2038 product 10849891 August 2038 product 11452721 August 2038 product 10449185 August 2038 product 7601740*PED October 2030 — 7601740 April 2030 substance, product 7732615*PED December 2028 — 7732615 June 2028 substance, product 7659285 August 2026 use U-1844
Regulatory exclusivity Code Expires PED October 2029 M-14 April 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.